` APLT (Applied Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

APLT
vs
S&P 500

Over the past 12 months, APLT has underperformed S&P 500, delivering a return of -86% compared to the S&P 500's +14% growth.

Stocks Performance
APLT vs S&P 500

Loading
APLT
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
APLT vs S&P 500

Loading
APLT
S&P 500
Difference
www.alphaspread.com

Performance By Year
APLT vs S&P 500

Loading
APLT
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Applied Therapeutics Inc vs Peers

S&P 500
APLT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Applied Therapeutics Inc
Glance View

Market Cap
18m USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
Not Available
Back to Top